Aptevo Therapeutics Inc. 8K

Aptevo Therapeutics reported Q2 2026 results, advanced its mipletamig AML program, appointed a new Chief Scientific Officer, secured a $1.5 million grant for APVO451, and entered a 50/50 radiopharmaceutical collaboration and equity deal with Niowave.

On August 14, 2026, Aptevo Therapeutics Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update, highlighting strong Phase 1b/2 RAINIER trial results for its lead candidate mipletamig in frontline acute myeloid leukemia, including high clinical benefit and remission rates and progress toward Phase 2 dose selection and a regulatory interaction targeted for early 2027. The company announced the appointment of Mary J. Janatpour, Ph.D., as Senior Vice President and Chief Scientific Officer to lead research and preclinical development across its oncology pipeline. Aptevo also disclosed receipt of a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment Fund to support IND-enabling work for its nectin-4–targeted trispecific solid tumor candidate APVO451, with development candidate selection expected by year-end 2026 and IND-enabling studies planned for the first quarter of 2027. In addition, Aptevo entered into a 50/50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, coupled with a strategic equity investment by Niowave that initially gives it a 7.9% ownership stake in Aptevo with the option to increase ownership up to 19.99%, providing Aptevo with access to radioisotope supply and a capital-efficient entry into radiopharmaceutical therapeutics. The company reported cash and cash equivalents of $9.8 million as of June 30, 2026 and disclosed that it raised $0.6 million during the quarter under Standby Equity Purchase Agreements with Yorkville.

Filing Facts

CIK

1671584

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-350537

Alert Tier

6